A 51-year-old European male with a history of hypertension presented with a 3-week history of progressive exertional dyspnoea, orthopnoea and paroxysmal nocturnal dyspnoea.
Full article available to subscribers
A 51-year-old European male with a history of hypertension presented with a 3-week history of progressive exertional dyspnoea, orthopnoea and paroxysmal nocturnal dyspnoea. There was no chest pain, smoking or relevant family history. Examination revealed a blood pressure rate of 220/160mmHg, a heart rate of 110bpm, jugular venous distension, diastolic murmur, basal crackles and peripheral oedema.
Investigations showed left ventricular hypertrophy on ECG and pulmonary oedema on chest X-ray. Troponin I was mildly elevated (49–51nmol/L), and NT-proBNP was 1823pmol/L. Transthoracic echocardiogram (TTE) revealed a mildly dilated left ventricle (5.6cm), severe global dysfunction (LVEF 24%), unicuspid aortic valve (UAV) with moderate-to-severe stenosis (AVA 1.1cm², mean gradient 19mmHg, velocity 3.1 m/s, DVI 0.26) and moderate regurgitation. Ascending aorta was dilated (53mm). Pulmonary artery systolic pressure was estimated at 60–65mmHg.
He was treated with intravenous furosemide, fluid restriction and heart failure medications including spironolactone, perindopril and metoprolol. Coronary angiography was normal. Right heart catheterisation revealed mean RA pressure of 2mmHg, mean PA pressure of 23mmHg, and PCWP of 11mmHg. After 2 weeks of optimisation, cardiac MRI showed improvement in LVEF to 34% and aortic regurgitant fraction of 16%. A computed tomography (CT) confirmed ascending aortic aneurysm and UAV.
View Figure 1–2.
The patient underwent a successful Bentall procedure with the placement of a 21mm On-X mechanical valve conduit. His post-operative recovery was uneventful. A follow-up TTE showed the prosthetic valve in situ with LVEF improved to 45–50%. He was discharged on day 10.
UAV is an exceptionally rare congenital anomaly, affecting approximately 0.02% of adults, but is found in 4–5% of patients undergoing surgery for isolated aortic stenosis. It results from incomplete separation of aortic valve cusps during embryogenesis. UAV exists in two forms: acommissural (severe stenosis early in life) and unicommissural (asymptomatic until the third to fifth decades). UAV is more common in males and is associated with aortic aneurysm, dissection and regurgitation.
Diagnosis relies on imaging, with TTE and cardiac MRI playing key roles. The hallmark of UAV on imaging is a teardrop-shaped systolic orifice. Treatment is surgical, with guidelines recommending aortic root replacement if the ascending aorta exceeds 5.0cm in diameter.
This case highlights the importance of recognising rare congenital causes of heart failure in middle-aged adults and the need for timely surgical intervention to prevent life-threatening complications.
Mona Alsomali: Cardiology Department, Auckland City Hospital, Auckland, New Zealand.
Nil.
1) Singh S, Ghayal P, Mathur A, et al. Unicuspid unicommissural aortic valve: an extremely rare congenital anomaly. Tex Heart Inst J. 2015 Jun 1;42(3):273-6. doi: 10.14503/THIJ-13-3634
2) Novaro GM, Mishra M, Griffin BP. Incidence and echocardiographic features of congenital unicuspid aortic valve in an adult population. J Heart Valve Dis. 2003 Nov;12(6):674-8
3) Losenno KL, Goodman RL, Chu MW. Bicuspid aortic valve disease and ascending aortic aneurysms: gaps in knowledge. Cardiol Res Pract. 2012;2012:145202. doi: 10.1155/2012/145202
4) Armstrong J, Crawford J, Arnautovic J. Unicuspid aortic valve replacement with development of complete heart block: a case report. Eur Heart J Case Rep. 2019 Mar 15;3(1):ytz026. doi: 10.1093/ehjcr/ytz026
5) Edwards JE. Pathologic aspects of cardiac valvular insufficiencies. AMA Arch Surg. 1958 Oct;77(4):634-49. doi: 10.1001/archsurg.1958.04370010166017
6) Roberts WC, Ko JM. Frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005 Feb 22;111(7):920-5. doi: 10.1161/01.CIR.0000155623.48408.C5
Sign in to view your account and access
the latest publications by the NZMJ.
Don't have an account?
Let's get started with creating an account.
Already have an account?
Become a member to enjoy unlimited digital access and support the ongoing publication of the New Zealand Medical Journal.
The New Zealand Medical Journal is fully available to individual subscribers and does not incur a subscription fee. This applies to both New Zealand and international subscribers. Institutions are encouraged to subscribe. The value of institutional subscriptions is essential to the NZMJ, as supporting a reputable medical journal demonstrates an institution’s commitment to academic excellence and professional development. By continuing to pay for a subscription, institutions signal their support for valuable medical research and contribute to the journal's continued success.
Please email us at nzmj@pmagroup.co.nz